Abstracts

Search by keyword or author name.

Showing 744 abstracts.

Pharmacokinetics, Safety, and Efficacy of Dolutegravir (DTG; S/GSK1349572) in HIV-1 Infected Adolescents: Preliminary analysis from IMPAACT 1093

Conference

XIX International AIDS Conference

Study

P1093

Size and Decay of the Resting CD4+ T Cell Latent HIV Reservoir in Early-Treated Infants.

Conference

XIX International AIDS Conference

Study

P1030

IMPAACT P1066: raltegravir (RAL) safety and efficacy in HIV infected (+) youth two to 18 years of age through week 48

Conference

XIX International AIDS Conference

Study

P1066

Tenofovir Disoproxil Fumarate (TDF) Pharmacokinetics (PK) with Daily Dosing in the First Week of Life (HPTN 057)

Conference

XIX International AIDS Conference

Association of Tenofovir Disoproxil Fumarate with Neonatal Growth

Conference

XIX International AIDS Conference

Study

P1025

Comparison of HIV-Genotyping Results Obtained from Next-generation Sequencing of Plasma and Dried Blood Spot Samples

Conference

XIX International AIDS Conference

Study

P1060

Effect of Pregnancy on Pharmacokinetics of Boosted Indinavir

Conference

13th International Workshop on Clinical Pharmacology of HIV Therapy

Study

P1026S

Raltegravir (RAL Pharmacokinetics (PK) and Safety in Neonates (IMPAACT P1097)

Conference

13th International Workshop on Clinical Pharmacology of HIV Therapy

Study

P1097

Impact of body weight on the risk of low lopinavir/r concentrations during the third trimester of pregnancy in HIV-infected Thai and US Women

Conference

13th International Workshop on Clinical Pharmacology of HIV Therapy

Interim Results from IMPAACT P1066: Raltegravir Oral Granules Formulation in Children 6 months to <2 Years of Age

Conference

19th Conference on Retroviruses and Opportunistic Infections

Study

P1066